Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer

J Cancer Res Clin Oncol. 2021 May;147(5):1421-1430. doi: 10.1007/s00432-021-03558-x. Epub 2021 Mar 3.

Abstract

Purpose: Sphingosine-kinase-1 (SPHK1) is a key enzyme of sphingolipid metabolism which is involved in ovarian cancer pathogenesis, progression and mechanisms of drug resistance. It is overexpressed in a variety of cancer subtypes. We investigated SPHK1 expression as a prognostic factor in epithelial ovarian cancer patients.

Methods: Expression analysis of SPHK1 was performed on formalin-fixed paraffin-embedded tissue from 1005 ovarian cancer patients with different histological subtypes using immunohistochemistry. Staining intensity of positive tumor cells was assessed semi-quantitatively, and results were correlated with clinicopathological characteristics and survival.

Results: In our ovarian cancer collective, high levels of SPHK1 expression correlated significantly with complete surgical tumor resection (p = 0.002) and lower FIGO stage (p = 0.04). Progression-free and overall survival were further significantly longer in patients with high-grade serous ovarian cancer and overexpression of SPHK1 (p = 0.002 and p = 0.006, respectively).

Conclusion: Our data identify high levels of SPHK1 expression as a potential favorable prognostic marker in ovarian cancer patients.

Keywords: Ovarian cancer; Prognosis; SPHK1.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism
  • Carcinoma, Ovarian Epithelial / metabolism*
  • Carcinoma, Ovarian Epithelial / mortality*
  • Female
  • Humans
  • Immunohistochemistry / methods
  • Middle Aged
  • Phosphotransferases (Alcohol Group Acceptor) / metabolism*
  • Prognosis
  • Progression-Free Survival
  • Young Adult

Substances

  • Biomarkers, Tumor
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase